Skip to main content

Table 1 Baseline Demographics and Clinical Features of CM

From: Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

Variable Enrolled Population N = 716
Mean (SD) age, y 43.0 (11.3)
Female, n (%) 607 (84.8)
Race, n (%)
 Caucasian 582 (81.3)
 Asian 89 (12.4)
 African American/black 41 (5.7)
 Other 4 (0.6)
Mean (SD) height, cm 165.8 (8.7)
Mean (SD) weight, kg 75.6 (19.8)
Mean (SD) BMI, kg/m2 27.4 (6.4)
Mean (SD) age of onset of CM, y 32.5 (13.7)
Mean (SD) time since onset of CM, y 10.6 (11.0)
Family history of migraine, yes, n (%) 449 (62.7)
Headache-related history,a n (%)
 Sleep disorder 210 (29.3)
 Smoking 150 (20.9)
 Head trauma 74 (10.3)
 Childhood abuse/maltreatment 50 (7.0)
Severity of pain during headache, n (%)
 Mild 3 (0.4)
 Moderate 296 (41.3)
 Severe 417 (58.2)
Pain on one or both sides of head, n (%)
 One 382 (53.4)
 Both 334 (46.6)
Type of head pain, n (%)
 Throbbing or pulsing 507 (70.8)
 Pressing or squeezing 170 (23.7)
 Neither throbbing, pulsing, pressing, squeezing 39 (5.4)
Severity of neck pain or stiffness, n (%)
 Mild 70 (9.8)
 Moderate 331 (46.2)
 Severe 157 (21.9)
 None 158 (22.1)
Other headache features, n (%)
 Sensitivity to light 658 (91.9)
 Physical activity worsens headache 642 (89.7)
 Sensitivity to noise 639 (89.2)
 Nausea with headache 583 (81.4)
 Vomiting with headache 295 (41.2)
 Cutaneous allodynia 290 (40.5)
Mean (SD) headache daysb 22.0 (4.8)
Mean (SD) moderate or severe headache daysb 18.0 (5.7)
Mean (SD) HIT-6 total scorec 64.7 (4.8)
  1. CM chronic migraine, HIT-6 6-item Headache Impact Test
  2. aPatients may be counted in > 1 category
  3. bHeadache days per 28 d in the analysis population (n = 715); includes 25 patients who reported < 15 headache days per 28 d at baseline
  4. cIn the analysis population (n = 715)